Survivor Stories
November 18, 2026 • 4 Min
Back to previous page

From Treatment to Surveillance

Bill Harrison

bald man with glasses hugging a woman with light hair in a sleeveless shirt.
  • Routine bloodwork leads to pancreatic cancer diagnosis
  • Chemotherapy with FOLFIRINOX, plus a clinical trial
  • Distal pancreatectomy shows no sign of cancer
  • Continuing surveillance

In the spring of 2025, I was a sixty-eight-year-old psychotherapist living in Chicago with my wife and cat.

I was planning to retire at the end of August, after having worked for 40 years as a professional musician and another 10 as a therapist in private practice. But on May 14, Dr. Steven Paterakos, my PCP, sent me to the ER because of a suspiciously high number on a D-dimer test for blood clotting. A CT scan they performed to check for blood clots revealed a 4 cm tumor on my pancreas. I had no discernible cancer symptoms. The doctors did an endoscopy to confirm that the tumor was, in fact, malignant. It turned out that I had pancreatic adenocarcinoma. The cancer had spread to several lymph nodes but, fortunately, hadn’t yet metastasized to any other organs.

On the Treatment Rollercoaster

Three weeks later, I began a regimen of chemotherapy at Northwestern Memorial Hospital under the care of Dr. Aparna Kalyan. She prescribed FOLFIRINOX, to be administered every two weeks. My doctor suggested I join a phase I trial of a medication called ASP2138, so I did. The medication was given as four injections into my abdomen just before every chemo infusion.

The months that followed were a rollercoaster ride of side effects, beginning with nausea, constipation, and diarrhea, along with “chemo brain,” debilitating fatigue, and eventually, acute neuropathy in my hands and feet, most likely caused by the oxaliplatin. I lost 45 pounds over the course of four months, mostly during bouts of post-infusion exhaustion paired with zero appetite and, frankly, repulsion at the sight of food.

Help me find a pancreatic cancer expert near me.

Learn more
Man walking toward clipboard

I closed my therapy practice on August 31. By that time, the tumor had become undetectable on CT scans and my CA 19-9 score had plummeted from a superhigh 745 to a remarkably low 37. The oncology staff was astounded that the cancer had responded so well, so quickly. They said I was a “unicorn,” that my body’s response to the chemotherapy was unprecedented. But there was no way they could be sure that the cancer cells either in the pancreas or in the lymph nodes had been eradicated. I understand that there’s no existing technology that allows us to peer into the human body at the cellular level without biopsies.

Managing Life on Treatment

Throughout this time, I had no confidence that I would outrun pancreatic cancer. I was well aware of the 12 percent five-year survival rate. I believed it was only a matter of time before things would start heading south; that my tumor would reemerge and that my numbers would start to climb back up. Dr. Kalyan decided that we should continue to stay the course with my chemotherapy, despite the success (on the one hand) and the continuing side effects (on the other). I no longer had lower GI problems, but the fatigue and neuropathy were still difficult to manage. Some cycles were terribly debilitating, while others were more or less tolerable. There didn’t seem to be much rhyme or reason why different infusions produced different degrees of side effects.

Then, in April of 2026, ten months into my treatment, my oncologist brought me the news that a group of thirty physicians, known (rather comically to me) as the tumor board, had concluded that my tumor was now resectable. This came as a huge surprise because, by that point, it seemed clear that I was going to be doing chemo forever. That’s the way it felt, anyway.

Time for Surgery

Dr. Brett Ecker performed a distal pancreatectomy (as opposed to a Whipple procedure) on June 9, which, as of this writing, is five months ago. The surgeon told me that the operation was, more than anything, diagnostic. The pathology report on tissue from my pancreas and from the lymph nodes showed no signs of cancer. There was no other way for the doctors to be sure that, as far as they can tell, there’s no longer any cancer in my body.

Life After Surgery

Dr. Kalyan told me there would be no follow-up treatment, just that I’d have to be monitored (or, as Dr. Ecker put it, surveilled) every three months with a CT scan and blood work. The neuropathy in my right hand has improved somewhat but, unfortunately, I still have a lot of numbness in the left hand and on the bottoms of both feet. If that’s the price I have to pay for being without detectable signs of cancer, so be it.